Finasteride (Propecia)

Subscribe to Selected New Research on Finasteride

755 relevant articles (107 outcomes, 260 trials/studies) found for this Drug

Description: An orally active TESTOSTERONE 5-ALPHA-REDUCTASE inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia.

Also Known As:

Propecia; Proscar; Cahill May Roberts Brand of Finasteride; Chibro-Proscar; Eucoprost; Frosst Iberica Brand of Finasteride; Lipha Brand of Finasteride; MK-906; MSD Brand of Finasteride; MSD Chibropharm Brand of Finasteride; Merck Brand 1 of Finasteride; Merck Brand 2 of Finasteride; Merck Frosst Brand 1 of Finasteride; Merck Frosst Brand 2 of Finasteride; Merck Sharp & Dhome Brand 2 of Finasteride; Merck Sharp & Dohme Brand 1 of Finasteride; Propeshia; Chibro Proscar; MK 906; MK906; 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)-

Relationship Network

Drug Context: Research Results

Experts

1.	Thompson, Ian M: 12 articles (05/2008 - 07/2003)
2.	Lippman, Scott M: 8 articles (05/2008 - 07/2003)
3.	Coltman, Charles A: 8 articles (05/2008 - 07/2003)
4.	Lucia, M Scott: 8 articles (02/2008 - 07/2003)
5.	Roehrborn, Claus G: 8 articles (11/2007 - 10/2003)
6.	Parnes, Howard L: 7 articles (05/2008 - 08/2006)
7.	Tangen, Catherine M: 6 articles (05/2008 - 07/2003)
8.	Goodman, Phyllis J: 6 articles (09/2007 - 07/2003)
9.	Kaplan, Steven A: 5 articles (01/2006 - 10/2002)
10.	McConnell, John D: 5 articles (01/2006 - 02/2002)

Related Diseases

1.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 11/01/2007 - "METHODS: One hundred twenty patients with a clinical diagnosis of benign prostatic hyperplasia (BPH), sexually active and with an International Index of Erectile Function-erectile function (IIEF-EF) domain >/=25 were randomized to receive finasteride 5 mg concealed as an "X compound of proven efficacy for the treatment of BPH" for 1 year with (group 2) or without (group 1) counseling on the drug sexual side effect" 01/01/1995 - "The total, obstructive and non-obstructive symptom scores decreased (improved) for patients on 1 and 5 mg finasteride, with the total score reducing by 33% from baseline at year 3. The results demonstrate that finasteride causes a modest but significant clinical improvement in men with urinary outflow obstruction secondary to benign prostatic hyperplasia." 04/01/2008 - "Two landmark multi-centre trials, MTOPS and PCPT, have shown that finasteride is an effective treatment of micturitional disorders due to benign prostatic hyperplasia, reducing the clinical progression of BPH" 02/01/2003 - "OBJECTIVES: To evaluate the safety and efficacy of finasteride 5 mg during a 10-year period in men with enlarged prostates from a single center who participated in the double-blind and extension phases of the multicenter, Phase III, North American benign prostatic hyperplasia (BPH) trial" 04/01/2002 - "There have been two large, international multicentre, phase III trials published documenting the safety and efficacy of finasteride in treating human benign prostatic hyperplasia" Order ALL the reference details at left...
2.	Alopecia (Baldness) 01/01/2008 - "No study has shown that 1 mg of finasteride effectively treats female androgenetic alopecia but doses of 2.5 and 5 mg finasteride have helped some women in a few open studies" 05/01/2008 - "BACKGROUND: Finasteride is a 5alpha-reductase inhibitor that has proved to be an effective treatment for men with androgenetic alopecia" 08/01/2002 - "Finasteride 1 mg/day is effective in the treatment of androgenetic alopecia (AGA)" 07/01/2001 - "Finasteride has been shown to be an effective treatment for men with androgenetic alopecia (AGA) as it restores hair growth to miniaturized hair follicles on the top of the scalp [1]" 06/01/1998 - "Type II, also present on the scalp, is the target of finasteride, a promising treatment for male pattern baldness" Order ALL the reference details at left...
3.	Hirsutism 10/01/2002 - "CONCLUSIONS: In this study, hirsutism scores decreased significantly at 6 and 12 months in both groups I and II. Low-dose (2.5 mg/day) finasteride is safe and cost effective in the treatment of hirsutism and may be used instead of high-dose finasteride (5 mg/day) therapy." 11/01/1998 - "A significant improvement of hirsutism was obtained by finasteride; clinical score observed at the 6th month of therapy was reduced from 11.71 +/- 2.23 to 7.92 +/- 1.81 (p < 0.05) and from 14.92 +/- 6.13 to 9.3 +/- 2.75 (p < 0.05) in group A and B, respectively" 08/01/1995 - "RESULTS: After 6 and 9 months of treatment, the hirsutism score improved significantly in the patients receiving finasteride, whereas no significant modifications were observed in patients treated with placebo" 03/01/2001 - "We believe that Diane 35 plus finasteride is an effective and safe combination for the treatment of hirsutism." 06/01/2004 - "Relative safety and efficacy of finasteride for treatment of hirsutism." Order ALL the reference details at left...
4.	Prostatic Neoplasms (Prostate Cancer) 08/01/1998 - "This study, using a novel model for evaluating short-term efficacy of chemopreventive or therapeutic agents in men at high risk of prostate cancer, provides little evidence that finasteride is an effective chemopreventive agent for prostate cancer in men with elevated PSA." 05/01/2008 - "METHODS: We used biospecimens from the Prostate Cancer Prevention Trial (PCPT), a phase III, double-blind, placebo-controlled trial that tested the efficacy of finasteride for the primary prevention of prostate cancer" 07/04/2007 - "BACKGROUND: The Prostate Cancer Prevention Trial (PCPT) was a randomized, double-blind, placebo-controlled study of the efficacy of finasteride in preventing prostate cancer in 18,882 men aged 55 years or older" 05/01/2000 - "PURPOSE: To describe men who agreed to be randomized to the Prostate Cancer Prevention Trial (PCPT), a 7-year, double-blind placebo-controlled study of the efficacy of finasteride in preventing prostate cancer" 12/01/2008 - "The Prostate Cancer Prevention Trial has clearly stated the chemopreventive properties of finasteride for prostate cancer but the necessity to provide such preventive therapy to a specific group of men with a higher risk to develop a clinically significant disease is under discussion" Order ALL the reference details at left...
5.	Hematuria 01/01/2001 - "CONCLUSION: Finasteride has proved to be a safe, well tolerable and effective medication in reducing or preventing recurrent hematuria related to BPH." 11/01/1995 - "CONCLUSIONS: Finasteride is effective in treating hematuria associated with BPH" 06/01/2002 - "RESULTS: Hematuria grade improved after finasteride in 50 (94%) patients" 02/01/1998 - "CONCLUSIONS: Long-term follow-up has confirmed the efficacy of finasteride in treating gross hematuria associated with BPH and we now recommend finasteride as first line therapy in the treatment of BPH-associated gross hematuria" 11/01/1995 - "RESULTS: Of the 12 patients with longer than 3 months of followup (mean 14) 11 improved according to the grade of hematuria after finasteride therapy" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Flutamide (Eulexin)
2.	Cholestenone 5 alpha-Reductase (5 alpha-Reductase)
3.	Minoxidil (Rogaine)
4.	Dihydrotestosterone (Androstanolone)
5.	Spironolactone (Aldactone)
6.	Testosterone (Sustanon)
7.	Doxazosin (Cardura)
8.	Cyproterone Acetate
9.	terazosine (terazosin)
10.	Hormones

Related Therapies and Procedures

1.	Chemoprevention
2.	Castration
3.	Drug Therapy (Chemotherapy)
4.	Balloon Dilatation
5.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Prostatic Hyperplasia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 356 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>